multidrug-resistant Pseudomonas aeruginosa infections in patients with hematological disease.
Conditions
Interventions
Colistin is administered intravenously. The dosage is 1.25-2.5mg/kg twice a day. The treetment period is between 3 and 28 days.
Sponsors
University of Tokyo Hospital Department of Hamatology and Oncology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 Patients with hematological disease. (Patients who received hematopoietic stem cell transplantation for non-hematological disease are included) 2 Multidrug-resistant Pseudomonas aeruginosa was detected by bacteria culture within one month 3 Patients with symptons due to Multidrug-resistant Pseudomonas aeruginosa infection 4 The patients who recieved intraveous antibiotic for more than three days within one week and the symptons of infection did not improve.
Exclusion criteria
Exclusion criteria: 1. Allergy for colistin 2. A woman who is pregnant or has chance to be pregnant.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A clinical response at the end of colistin therapy | — |
Countries
Japan
Contacts
Public ContactFumihiko Nakamura
University of Tokyo Hospital Hematology and Oncology
Outcome results
None listed